Allergy Therapeutics PLC (AIM:AGY) has presented new data showing the use of its grass pollen vaccine can cut hay fever symptoms by around 40%.
Posters from its two lead immunotherapy programmes were shown at the 2022 American Academy of Allergy Asthma and Immunology Annual Meeting held in Phoenix, Arizona.
Results from the field trial of Grass MATA MPL, an injectable treatment for grass pollen allergy, were better compared to the placebo group than previously reported
An improvement in symptoms of 39.5% was recorded against the 36.8% figure initially reported in October 2021.
Allergy also presented post-hoc analyses of an earlier Phase II grass trial highlighting the strong predictive value of the baseline conjunctival provocation test score, which it said will help frame the Phase III trial that is scheduled to commence in the autumn.
Ahead of that trial, Allergy also unveiled new procedures to measure accurately daily pollen counts and better establish the peak grass pollen season.
Elsewhere, Allergy also presented data from a biomarker study (VLP001) of its peanut allergy treatment development VLP Peanut that indicated it does not elicit an allergic reaction and results in a significant reduction in the allergens that spark a reaction.
Manuel Llobet, Allergy's chief executive, said: "Demonstrating a nearly 40% reduction in combined symptom and medication score compared to placebo in a grass pollen allergy trial is a significant event in our history.
"We are very much looking forward to the pivotal G306 clinical trial of our Grass MATA MPL immunotherapy that is due to commence later this year and, if successful, would enable registration in Europe and the US.
"I am also very proud to see the data from our VLP001 study being presented internationally - data that provides us with confidence in the product profile of our novel short course peanut allergy vaccine candidate."